Litcius/Paper detail

The Modified Glasgow Prognostic Score and Prognostic Nutritional Index as Prognostic Markers in Patients With Metastatic Breast Cancer Treated With Eribulin

Shinya Yamamoto, Shoko Adachi, Tomoko Wada, Kazutaka Narui, Aki Kimura, Masanori Oshi, Akimitsu Yamada, Toshihiro Misumi, Itaru Endo

2022In Vivo15 citationsDOIOpen Access PDF

Abstract

AIM: To examine the role of the Modified Glasgow Prognostic Score (mGPS) and Prognostic Nutritional Index (PNI) as prognostic markers for patients with metastatic breast cancer (MBC). PATIENTS AND METHODS: We investigated the associations of clinico-pathological factors with time-to-treatment failure (TTF) and overall survival (OS) in 110 patients with MBC treated with eribulin. RESULTS: C-Reactive protein >1 mg/dl, albumin <3.5 g/dl, mGPS=2, and PNI <40 were significant predictors of shorter TTF in univariate analyses. PNI <40 remained a significant and independent predictor of shorter TTF in multivariate analyses. De novo tumor, visceral metastases, C-reactive protein >1 mg/dl, albumin <3.5 g/dl, mGPS=2, and PNI <40 were significant predictors of poor OS at the univariate level. A PNI <40 was a significant and independent predictor of poor OS in multivariate analyses. CONCLUSION: PNI is a reliable predictor of TTF and OS in patients with MBC treated with eribulin.

Topics & Concepts

EribulinMedicineInternal medicineOncologyMetastatic breast cancerBreast cancerOverall survivalCancerInflammatory Biomarkers in Disease PrognosisCancer, Lipids, and MetabolismNutrition and Health in Aging